Earnings Call · Q1 FY2022·2022-05-16

Q1 22EPS -42.25%·Rev n/aQ4 21EPS -30.55%·Rev n/aQ3 21EPS -10.00%·Rev n/aQ2 21EPS 0.00%·Rev n/a⚠ consensus missing

TherapeuticsMD, Inc. TXMD

Lisa Wilson — Investor Relations

Hugh O'Dowd — Chief Executive Officer

Michael Donegan — Chief Financial Officer

−14.0%1d on move date−16.1% vs SPY3d−27.7%5d−18.5%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more TXMD calls or request research access.

More TXMD calls Browse calls Request research access